401 related articles for article (PubMed ID: 24166406)
1. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.
Poels EM; Kegeles LS; Kantrowitz JT; Slifstein M; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
Mol Psychiatry; 2014 Jan; 19(1):20-9. PubMed ID: 24166406
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.
Poels EM; Kegeles LS; Kantrowitz JT; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
Schizophr Res; 2014 Feb; 152(2-3):325-32. PubMed ID: 24418122
[TBL] [Abstract][Full Text] [Related]
3. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
Stone JM
Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
[TBL] [Abstract][Full Text] [Related]
4. The cytokine model of schizophrenia: emerging therapeutic strategies.
Girgis RR; Kumar SS; Brown AS
Biol Psychiatry; 2014 Feb; 75(4):292-299. PubMed ID: 24439555
[TBL] [Abstract][Full Text] [Related]
5. The association between
Beck K; Arumuham A; Brugger S; McCutcheon RA; Veronese M; Santangelo B; McGinnity CJ; Dunn J; Kaar S; Singh N; Pillinger T; Borgan F; Sementa T; Neji R; Jauhar S; Aigbirhio F; Boros I; Turkheimer F; Hammers A; Lythgoe D; Stone J; Howes OD
J Psychopharmacol; 2022 Sep; 36(9):1051-1060. PubMed ID: 36120998
[TBL] [Abstract][Full Text] [Related]
6. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
7. Glutamatergic theories of schizophrenia.
Javitt DC
Isr J Psychiatry Relat Sci; 2010; 47(1):4-16. PubMed ID: 20686195
[TBL] [Abstract][Full Text] [Related]
8. A Review of Molecular Imaging of Glutamate Receptors.
Kim JH; Marton J; Ametamey SM; Cumming P
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081223
[TBL] [Abstract][Full Text] [Related]
9. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
[TBL] [Abstract][Full Text] [Related]
10. Glutamate-mediated excitotoxicity in schizophrenia: a review.
Plitman E; Nakajima S; de la Fuente-Sandoval C; Gerretsen P; Chakravarty MM; Kobylianskii J; Chung JK; Caravaggio F; Iwata Y; Remington G; Graff-Guerrero A
Eur Neuropsychopharmacol; 2014 Oct; 24(10):1591-605. PubMed ID: 25159198
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical brain imaging investigations of schizophrenia.
Soares JC; Innis RB
Biol Psychiatry; 1999 Sep; 46(5):600-15. PubMed ID: 10472414
[TBL] [Abstract][Full Text] [Related]
12. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
Gomes FV; Grace AA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
[TBL] [Abstract][Full Text] [Related]
13. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.
Salavati B; Rajji TK; Price R; Sun Y; Graff-Guerrero A; Daskalakis ZJ
Schizophr Bull; 2015 Jan; 41(1):44-56. PubMed ID: 25249654
[TBL] [Abstract][Full Text] [Related]
14. [To Test Glutamate Hypothesis for Schizophrenia Utilizing Proton Magnetic Resonance Spectroscopy].
Tsugawa S; Nakajima SL
Brain Nerve; 2017 Sep; 69(9):1035-1040. PubMed ID: 28900066
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the glycine cleavage system genes possibly affect the negative symptoms of schizophrenia through metabolomic profile changes.
Yoshikawa A; Nishimura F; Inai A; Eriguchi Y; Nishioka M; Takaya A; Tochigi M; Kawamura Y; Umekage T; Kato K; Sasaki T; Ohashi Y; Iwamoto K; Kasai K; Kakiuchi C
Psychiatry Clin Neurosci; 2018 Mar; 72(3):168-179. PubMed ID: 29232014
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T.
Kim SY; Kaufman MJ; Cohen BM; Jensen JE; Coyle JT; Du F; Öngür D
Biol Psychiatry; 2018 Mar; 83(6):484-491. PubMed ID: 29031411
[TBL] [Abstract][Full Text] [Related]
17. Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction.
Kosten L; Verhaeghe J; Verkerk R; Thomae D; De Picker L; Wyffels L; Van Eetveldt A; Dedeurwaerdere S; Stroobants S; Staelens S
Psychiatry Res Neuroimaging; 2016 Feb; 248():1-11. PubMed ID: 26803479
[TBL] [Abstract][Full Text] [Related]
18. Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study.
Rao N; Northoff G; Tagore A; Rusjan P; Kenk M; Wilson A; Houle S; Strafella A; Remington G; Mizrahi R
Schizophr Bull; 2019 Apr; 45(3):670-679. PubMed ID: 29878197
[TBL] [Abstract][Full Text] [Related]
19. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.
Marsman A; van den Heuvel MP; Klomp DW; Kahn RS; Luijten PR; Hulshoff Pol HE
Schizophr Bull; 2013 Jan; 39(1):120-9. PubMed ID: 21746807
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia.
Gulchina Y; Xu SJ; Snyder MA; Elefant F; Gao WJ
J Neurochem; 2017 Nov; 143(3):320-333. PubMed ID: 28628228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
